Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires $348,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 200,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $1.74 per share, with a total value of $348,000.00. Following the completion of the transaction, the chief executive officer now directly owns 213,501,448 shares in the company, valued at $371,492,519.52. The trade was a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, February 28th, Phillip Md Et Al Frost purchased 67,434 shares of OPKO Health stock. The stock was bought at an average cost of $1.71 per share, with a total value of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost bought 47,537 shares of OPKO Health stock. The stock was purchased at an average cost of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.48 per share, with a total value of $740,000.00.

OPKO Health Stock Up 3.9 %

OPKO Health stock opened at $1.86 on Thursday. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -9.79 and a beta of 1.70. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The stock has a 50 day moving average of $1.64 and a two-hundred day moving average of $1.57. OPKO Health, Inc. has a twelve month low of $0.87 and a twelve month high of $2.04.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, research analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

OPK has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Wednesday. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Wednesday, March 12th.

Institutional Trading of OPKO Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP grew its position in shares of OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after purchasing an additional 4,284,336 shares during the period. Millennium Management LLC increased its holdings in shares of OPKO Health by 85.3% during the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after buying an additional 2,112,382 shares during the last quarter. Northern Trust Corp raised its position in shares of OPKO Health by 4.7% in the 4th quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company’s stock worth $5,436,000 after buying an additional 164,847 shares during the period. Lazard Asset Management LLC boosted its holdings in OPKO Health by 143.6% in the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after acquiring an additional 1,502,342 shares during the last quarter. Finally, Two Sigma Investments LP boosted its holdings in OPKO Health by 136.1% in the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock valued at $2,422,000 after acquiring an additional 949,671 shares during the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.